Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Launches Acicept Jelly Formulation

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Eisai Dec. 2 launched a jelly formulation of its blockbuster drug Aricept (donepezil) for Alzheimer's disease. The new formulation comes in three dosages: 3mg, 5mg and 10mg. Eisai hopes to maximize Aricpet product value through adding new formulations before the basic patent for the drug expires in November 2010. The company also launched a fine granule formulation. Eisai said the addition will make Aricept easier to take for senior AD patients who have difficulty swallowing. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070723

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel